Beaird Harris Wealth Management LLC Has $264,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Beaird Harris Wealth Management LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 17.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 453 shares of the company’s stock after purchasing an additional 67 shares during the quarter. Beaird Harris Wealth Management LLC’s holdings in Eli Lilly and Company were worth $264,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth $234,000. Loomis Sayles & Co. L P increased its holdings in shares of Eli Lilly and Company by 324.2% during the third quarter. Loomis Sayles & Co. L P now owns 1,069 shares of the company’s stock worth $574,000 after purchasing an additional 817 shares during the period. Financial Engines Advisors L.L.C. raised its position in shares of Eli Lilly and Company by 23.6% in the third quarter. Financial Engines Advisors L.L.C. now owns 1,038 shares of the company’s stock valued at $557,000 after buying an additional 198 shares in the last quarter. Phoenix Holdings Ltd. raised its position in shares of Eli Lilly and Company by 20.6% in the third quarter. Phoenix Holdings Ltd. now owns 6,350 shares of the company’s stock valued at $3,417,000 after buying an additional 1,083 shares in the last quarter. Finally, QRG Capital Management Inc. bought a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $56,826,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on LLY shares. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, Argus increased their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $787.53.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold 552,804 shares of company stock worth $462,119,714 over the last ninety days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 0.6 %

NYSE:LLY traded down $4.88 during mid-day trading on Friday, hitting $878.45. 2,023,264 shares of the company’s stock were exchanged, compared to its average volume of 2,475,545. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $885.06. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $834.89 billion, a P/E ratio of 129.37, a PEG ratio of 1.93 and a beta of 0.36. The company has a 50 day simple moving average of $785.96 and a 200-day simple moving average of $717.55.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.62 earnings per share. As a group, research analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were paid a $1.30 dividend. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.59%. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.